| Literature DB >> 36057576 |
Xin-Yu Lu1,2, Ji-Yun Zhang1, Tao Zhang3, Xue-Qin Zhang4, Jian Lu1, Xiao-Fen Miao1, Wei-Bo Chen5, Ji-Feng Jiang1, Ding Ding1, Sheng Du1.
Abstract
OBJECTIVES: We aimed to investigate the value of performing gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) enhanced magnetic resonance imaging (MRI) radiomics for preoperative prediction of microvascular invasion (MVI) of hepatocellular carcinoma (HCC) based on multiple sequences.Entities:
Keywords: Contrast media; Hepatocellular carcinoma; Magnetic resonance imaging; Microvascular invasion; Radiomics
Mesh:
Substances:
Year: 2022 PMID: 36057576 PMCID: PMC9440540 DOI: 10.1186/s12880-022-00855-w
Source DB: PubMed Journal: BMC Med Imaging ISSN: 1471-2342 Impact factor: 2.795
Fig. 1Flowchart of the enrollment of patients
The parameters of the scan sequences
| TR (ms) | TE (ms) | Slice thickness (mm) | Slice gap (mm) | Matrix | |
|---|---|---|---|---|---|
| T2WI | 2000 | 70.0 | 5.0 | 1.0 | 250 × 230 |
| DWI | 3000–5000 | 55.0 | 5.0 | 1.0 | 128 × 160 |
| In-phase/out-phase T1WI | 150 | 2.3/1.15 | 7.0 | 1.0 | 250 × 230 |
| THRIVE | 3 | 1.5 | 2.5 | 0 | 250 × 230 |
T2WI T2-weighted imaging, DWI diffusion-weighted imaging, T1WI T1-weighted imaging, THRIVE high-resolution isotropic volume excitation sequence
Fig. 2The delineation of ROI on T2WI (a), DWI (b), T1WI (c), AP (d), PP (e), TP (f) and HBP (g). The ROI was drawn as close to the margin of the tumour as possible but within the margin on the largest section
Comparison of the baseline data of the clinicoradiological data
| Training set (n = 115) | Validation set (n = 50) | ||||||
|---|---|---|---|---|---|---|---|
| MVI-negative (n = 81) | MVI-positive (n = 34) | MVI-negative (n = 35) | MVI-positive (n = 15) | ||||
| Sex | 1.00 | 0.30 | 0.65 | ||||
| 0, Female | 32 (39.5) | 13 (38.2) | 14 (40.0) | 3 (20.0) | |||
| 1, Male | 49 (60.5) | 21 (61.8) | 21 (60.0) | 12 (80.0) | |||
| Multifocality | 1.00 | 1.00 | 0.55 | ||||
| 0, No | 69 (85.2) | 29 (85.3) | 28 (80.0) | 12 (80.0) | |||
| 1, Yes | 12 (14.8) | 5 (14.7) | 7 (20.0) | 3 (20.0) | |||
| Cirrhosis | |||||||
| 0, No | 5 (6.2) | 3 (8.8) | 0.92 | 2 (5.7) | 2 (13.3) | 0.73 | 0.47 |
| 1, Yes | 76 (93.8) | 31 (91.2) | 33 (94.3) | 13 (86.7) | |||
| HBsAg | 0.64 | 0.93 | 0.96 | ||||
| 0, Negative | 14 (17.3) | 4 (11.8) | 5 (14.3) | 3 (20.0) | |||
| 1, Positive | 67 (82.7) | 30 (88.2) | 30 (85.7) | 12 (80.0) | |||
| Tumour signal on T2WI | 0.06 | 1.00 | 0.67 | ||||
| 0, Homogeneous | 15 (18.5) | 1 (2.9) | 4 (11.4) | 1 (6.7) | |||
| 1, Heterogeneous | 66 (81.5) | 33 (97.1) | 31 (88.6) | 14 (93.3) | |||
| Peritumoural enhancement | 0.65 | 0.05 | 0.45 | ||||
| 0, No | 71 (87.7) | 28 (82.4) | 31 (88.6) | 9 (60.0) | |||
| 1, Yes | 10 (12.3) | 6 (17.6) | 4 (11.4) | 6 (40.0) | |||
| Tumour capsule | < 0.001 | 0.34 | 0.17 | ||||
| 0, Absent | 25 (30.9) | 8 (23.5) | 11 (31.4) | 3 (20.0) | |||
| 1, Incomplete | 7 ( 8.6) | 15 (44.1) | 9 (25.7) | 7 (46.7) | |||
| 2, Complete | 49 (60.5) | 11 (32.4) | 15 (42.9) | 5 (33.3) | |||
| Tumour margin | < 0.001 | 0.10 | 0.07 | ||||
| 0, Smooth | 62 (76.5) | 12 (35.3) | 20 (57.1) | 4 (26.7) | |||
| 1, Non-smooth | 19 (23.5) | 22 (64.7) | 15 (42.9) | 11 (73.3) | |||
| Peritumoural hypointensity | < 0.001 | 0.01 | 0.51 | ||||
| 0, No | 75 (92.6) | 17 (50.0) | 30 (85.7) | 7 (46.7) | |||
| 1, Yes | 6 (7.4) | 17 (50.0) | 5 (14.3) | 8 (53.3) | |||
| Age | 58.00 [52.00, 65.00] | 60.00 [51.50, 64.00] | 0.95 | 57.00 [50.00, 63.50] | 55.00 [52.50, 63.50] | 0.76 | 0.67 |
| Tumour size | 2.18 [1.60, 3.18] | 3.68 [2.70, 5.79] | < 0.001 | 2.68 [1.95, 3.65] | 4.20 [3.30, 5.33] | 0.01 | 0.90 |
| AFP | 8.19 [3.32, 89.75] | 25.98 [3.50, 183.14] | 0.24 | 50.29 [6.24, 225.46] | 22.14 [6.17, 82.26] | 0.62 | 0.52 |
| ALT | 30.00 [22.00, 46.00] | 28.50 [22.25, 46.00] | 0.62 | 30.00 [23.50, 44.00] | 30.00 [17.50, 46.50] | 0.66 | 0.78 |
| AST | 36.00 [27.00, 50.00] | 35.50 [26.50, 45.00] | 0.58 | 38.00 [27.00, 53.50] | 32.00 [26.00, 38.00] | 0.22 | 0.88 |
| ALB | 42.10 [38.80, 44.30] | 42.05 [38.25, 44.85] | 0.69 | 40.60 [37.40, 44.55] | 42.50 [39.75, 44.70] | 0.44 | 0.81 |
| TBIL | 15.90 [12.70, 21.30] | 15.40 [11.88, 18.78] | 0.27 | 15.00 [11.95, 22.75] | 16.50 [12.30, 20.95] | 0.90 | 0.68 |
| DBIL | 5.30 [4.10, 7.10] | 4.55 [4.03, 6.68] | 0.26 | 5.40 [3.85, 7.90] | 6.30 [3.40, 7.30] | 0.97 | 0.43 |
| PLT | 111.00 [69.00, 144.00] | 109.50 [82.75, 146.75] | 0.32 | 107.00 [80.50, 127.00] | 145.00 [102.50, 207.00] | 0.04 | 0.34 |
| PT | 12.50 [11.60, 13.40] | 11.80 [11.20, 12.33] | 0.04 | 12.60 [11.90, 13.40] | 11.90 [11.65, 12.40] | 0.11 | 0.13 |
| INR | 1.07 [0.99, 1.17] | 1.01 [0.96, 1.05] | 0.02 | 1.08 [1.02, 1.15] | 1.05 [1.00, 1.08] | 0.15 | 0.45 |
P*, P value for the test between the training set and the validation set
MVI microvascular invasion, HBsAg hepatitis B surface antigen, T2WI T2-weighted imaging, AFP alpha-fetoprotein, ALT alanine-aminotransferase, AST aspartate-aminotransferase, ALB albumin, TBIL total bilirubin, DBIL direct bilirubin, PLT platelets, PT prothrombin time, INR international normalised ratio
The univariate logistic regression analysis of each variable with OR in the validation set of the clinicoradiological model
| OR | 95% CI | ||
|---|---|---|---|
| Tumour capsule | 0.55 | 0.30–0.98 | 0.006 |
| Tumour margin | 4.46 | 1.49–13.35 | 0.006 |
| Peritumoural hypointensity | 6.15 | 1.64–23.06 | 0.006 |
| Tumour size | 1.29 | 0.96–1.73 | 0.082 |
| AST | 0.98 | 0.94–1.01 | 0.143 |
| ALB | 0.90 | 0.79–1.04 | 0.095 |
| PT | 0.74 | 0.53–1.01 | 0.055 |
OR odds ratio, CI confidence interval, AST aspartate-aminotransferase, ALB albumin, PT prothrombin time
The univariate logistic regression analysis of each variable with OR in the validation set of the radiomics model
| Sequence | Feature | OR | 95% CI | |
|---|---|---|---|---|
| TP | Wavelet.GLDM.LLH_DV | 1.39 | (1.01–1.91) | 0.041 |
| PP | GLCM_IDN | 1.54 | (1.11–2.14) | 0.008 |
| T1WI | Exponential.GLDM_DV | 1.19 | (1.01–1.40) | 0.028 |
| DWI | Wavelet.FirstOrder.LLL_Range | 1.09 | (0.46–2.58) | 0.851 |
| DWI | Wavelet.GLSZM.HLL_SZN | 2.25 | (0.83–6.07) | 0.107 |
| DWI | SquareRoot.GLSZM_SZN | 9.12 | (1.82–15.78) | 0.004 |
| DWI | Logarithm.GLSZM_SAHGLE | 1.04 | (1.02–1.06) | 0.030 |
| T2WI | Wavelet.FirstOrder.HLL_Maximum | 2.70 | (1.16–6.28) | 0.012 |
DV measures the variance in dependence size in the image; ID normalizes the difference between the neighboring intensity values; Range represents the range of gray values in the ROI; SZN measures the variability of size zone volumes in the image; SAHGLE measures the proportion in the image of the joint distribution of smaller size zones with higher gray-level values; Maximum is the maximum gray level intensity within the ROI
OR odds ratio, CI confidence interval, TP transitional phase, PP portal venous phase, T1WI T1-weighted imaging, DWI,diffusion-weighted imaging, T2WI T2-weighted imaging, GLDM grey-level dependence matrix, GLCM grey-level co-occurrence matrix, GLSZM grey-level size-zone matrix, DV dependence variance, IDN inverse difference normalized, SZN size zone non-uniformity, SAHGLE small area high gray level emphasis
Fig. 3The correlation coefficient heatmap for clinicoradiological variables and radiomics features selected in the radiomics model. The larger the value or the darker the color is, the stronger the correlation is
Fig. 4LASSO algorithm used for the combined model. a The variation of the coefficients of the variables with the penalty coefficient (λ) b Use tenfold cross-validation to select λ. When the binomial deviation was the smallest (minimum standard), nine nonzero coefficients were determined
Fig. 5Forest plot showing the univariate logistic regression analysis of each variable with OR in the validation set of the combined model
Fig. 6Construction of the nomogram. The point of each variable was added up to obtain the total points. The total point corresponded to the risk probability of predicting MVI. The nomogram can be used to predict the risk probability of MVI for each patient
Fig. 7Calibration curve of the nomogram model
The performances of the models in predicting MVI
| Training set | Validation set | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUC | 95% CI | Sen (%) | Spe (%) | AUC | 95% CI | Sen (%) | Spe (%) | |||
| Clinicoradiological model | 0.715 | 0.678–0.745 | 51.88 | 91.67 | 0.003 | 0.708 | 0.677–0.719 | 50.33 | 92.07 | 0.041 |
| Radiomics model | 0.782 | 0.734–0.801 | 63.71 | 82.80 | 0.012 | 0.755 | 0.721–0.786 | 84.50 | 80.78 | 0.012 |
| Combined model | 0.841 | 0.822–0.867 | 81.43 | 72.76 | 0.007 | 0.826 | 0.798–0.838 | 90.89 | 69.85 | 0.026 |
AUC area under the ROC curve, CI confidence interval, Sen sensitivity, Spe specificity